NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
9.45
+0.49 (5.47%)
At close: Dec 10, 2025, 4:00 PM EST
9.27
-0.18 (-1.90%)
After-hours: Dec 10, 2025, 7:14 PM EST
NTHI Employees
NeOnc Technologies Holdings had 8 employees as of December 31, 2023.
Employees
8
Change
n/a
Growth
n/a
Revenue / Employee
$7,499
Profits / Employee
-$6,109,386
Market Cap
184.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NTHI News
- 9 days ago - NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors - GlobeNewsWire
- 27 days ago - NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program - GlobeNewsWire
- 2 months ago - NeOnc Technologies: From Survival Mode To Expansion Mode - Seeking Alpha
- 2 months ago - NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors - GlobeNewsWire
- 2 months ago - NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board - GlobeNewsWire
- 3 months ago - Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy - GlobeNewsWire
- 3 months ago - NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer - GlobeNewsWire